Recent evidence suggests that the mechanism underlying CMT2D involves extracellular neomorphic binding of mutant GlyRS to neuronally-expressed proteins. This evidence concerns the gene GARS1 and Autosomal dominant Charcot-Marie-Tooth disease type 2D.